NCT06640413View on ClinicalTrials.gov

A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

December 31, 2028

Conditions

FAP

Interventions

DRUG

[177Lu]Lu-OncoFAP-23

3.7, 7.4, or 11.1 GBq to define the RD

DRUG

L19IL2

22.5 Mio IU

Trial Locations (4)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20141

Istituto Europeo di Oncologia, Milan

24127

ASST Papa Giovanni XXIII Piazza OMS, Bergamo

80131

"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Via Mariano Semmola", Napoli

All Listed Sponsors

lead

Philogen S.p.A.

INDUSTRY

NCT06640413 - A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors | Biotech Hunter | Biotech Hunter